Eliem Therapeutics Earnings Estimate
| ELYMDelisted Stock | USD 3.04 0.19 5.88% |
Eliem |
Eliem Therapeutics Earnings Estimation Breakdown
The calculation of Eliem Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Eliem Therapeutics is estimated to be 0.0 with the future projection ranging from a low of 0.0 to a high of 0.0. Please be aware that this consensus of annual earnings estimates for Eliem Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.00 Lowest | Expected EPS | 0.00 Highest |
Eliem Therapeutics Earnings Projection Consensus
Suppose the current estimates of Eliem Therapeutics' value are higher than the current market price of the Eliem Therapeutics stock. In this case, investors may conclude that Eliem Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Eliem Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 0 | 87.62% | -0.1314 | 0.0 | -2.22 |
Eliem Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of Eliem Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Eliem Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Eliem Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Eliem Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Eliem Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Eliem Therapeutics should always be considered in relation to other companies to make a more educated investment decision.Eliem Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Eliem Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-13 | 2024-03-31 | 0 | -0.0614 | -0.0614 | 0 | ||
2024-03-28 | 2023-12-31 | -0.13 | -0.1314 | -0.0014 | 1 | ||
2023-11-14 | 2023-09-30 | -0.14 | -0.1466 | -0.0066 | 4 | ||
2023-08-10 | 2023-06-30 | -0.16 | -0.1945 | -0.0345 | 21 | ||
2023-05-11 | 2023-03-31 | -0.25 | -0.25 | 0.0 | 0 | ||
2023-03-06 | 2022-12-31 | -0.38 | -0.29 | 0.09 | 23 | ||
2022-11-14 | 2022-09-30 | -0.43 | -0.37 | 0.06 | 13 | ||
2022-08-15 | 2022-06-30 | -0.47 | -0.56 | -0.09 | 19 | ||
2022-05-16 | 2022-03-31 | -0.56 | -0.5 | 0.06 | 10 | ||
2022-03-07 | 2021-12-31 | -0.62 | -0.4 | 0.22 | 35 | ||
2021-11-08 | 2021-09-30 | -0.92 | -0.7 | 0.22 | 23 | ||
2021-09-13 | 2021-06-30 | -1.86 | -3.11 | -1.25 | 67 |
About Eliem Therapeutics Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Eliem Therapeutics earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Eliem Therapeutics estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Eliem Therapeutics fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | -156 M | -148.2 M | |
| Retained Earnings Total Equity | -108.8 M | -114.2 M | |
| Earnings Yield | (0.48) | (0.51) | |
| Price Earnings Ratio | (2.07) | (2.18) | |
| Price Earnings To Growth Ratio | 0.08 | 0.07 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eliem Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Consideration for investing in Eliem Stock
If you are still planning to invest in Eliem Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eliem Therapeutics' history and understand the potential risks before investing.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |